PD-L1 Targeting Molecular Imaging of Solid Tumors
ConditionGastrointestinal Tumors
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking University Cancer Hospital & Institute
About this trial
The objective of the study is to constrcut a noninvasive approach WL12 PET/CT to detect the PD-L1 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from anti-PD-1/L1 treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
1. Aged >18 years old; ECOG 0 or 1;
2. Patients with Gastrointestinal tumors;
3. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
4. life expectancy >=12 weeks.
Disqualifiers
1. Significant hepatic or renal dysfunction;
2. Is pregnant or ready to pregnant;
3. Cannot keep their states for half an hour;
4. Refusal to join the clinical study;
Trial design
Design model
Single group
Treatments tested in this trial
68Ga-WL12 PET/CT
Other interventionWL12, labeled with PET radio-nuclide ( Ga-68 )will be used as a molecular imaging tracer for PET/CT scanning
Treatment groups
20 Participants
are divided into 1 treatment groupGroup A: Imaging cohortExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Standardized uptake value（SUV）
The uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value（SUV）on PET/CT
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov